1.05
price down icon3.67%   -0.04
after-market Dopo l'orario di chiusura: 1.10 0.05 +4.76%
loading
Precedente Chiudi:
$1.09
Aprire:
$1.07
Volume 24 ore:
386.96K
Relative Volume:
0.93
Capitalizzazione di mercato:
$59.68M
Reddito:
$19.94M
Utile/perdita netta:
$-37.37M
Rapporto P/E:
-1.0096
EPS:
-1.04
Flusso di cassa netto:
$-33.38M
1 W Prestazione:
-16.00%
1M Prestazione:
-13.22%
6M Prestazione:
-29.05%
1 anno Prestazione:
-55.32%
Intervallo 1D:
Value
$1.025
$1.119
Intervallo di 1 settimana:
Value
$1.015
$1.27
Portata 52W:
Value
$0.595
$4.18

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name
Nome
Werewolf Therapeutics Inc
Name
Telefono
617-952-0555
Name
Indirizzo
200 TALCOTT AVENUE, WATERTOWN
Name
Dipendente
46
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
HOWL's Discussions on Twitter

Confronta HOWL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
HOWL
Werewolf Therapeutics Inc
1.05 59.68M 19.94M -37.37M -33.38M -1.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-04-03 Iniziato JMP Securities Mkt Outperform
2023-08-24 Iniziato Wedbush Outperform
2023-06-06 Ripresa Jefferies Buy
2021-09-10 Iniziato BofA Securities Buy
2021-05-25 Iniziato Evercore ISI Outperform
2021-05-25 Iniziato H.C. Wainwright Buy
2021-05-25 Iniziato Jefferies Buy
2021-05-25 Iniziato SVB Leerink Outperform
Mostra tutto

Werewolf Therapeutics Inc Borsa (HOWL) Ultime notizie

pulisher
Jun 14, 2025

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Werewolf Therapeutics Adopts New Bylaws and Elects Directors - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Sells 87,168 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewswire

Jun 12, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Acquires 39,564 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Sells 117,200 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 03, 2025

Deutsche Bank AG Buys 83,172 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 03, 2025
pulisher
Jun 01, 2025

Northern Trust Corp Acquires 16,640 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 01, 2025
pulisher
Jun 01, 2025

Bank of America Corp DE Lowers Stock Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Werewolf Therapeutics Announces Q1 2025 Financial Results - MSN

May 31, 2025
pulisher
May 29, 2025

Werewolf Therapeutics Leaders to Reveal Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Werewolf Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Makes New Investment in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

May 29, 2025
pulisher
May 27, 2025

Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy R - GuruFocus

May 27, 2025
pulisher
May 24, 2025

Werewolf Therapeutics (HOWL) Stock Price, News & Analysis - MarketBeat

May 24, 2025
pulisher
May 22, 2025

Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com Australia

May 22, 2025
pulisher
May 20, 2025

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough Skin Cancer Treatment: Patient Cancer-Free After 1 Year in Revolutionary IL-2 Drug Trial - Stock Titan

May 20, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Cuts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

May 18, 2025
pulisher
May 15, 2025

Werewolf Therapeutics Receives Nasdaq Deficiency Notice - TipRanks

May 15, 2025
pulisher
May 13, 2025

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit - GlobeNewswire

May 13, 2025
pulisher
May 12, 2025

Wedbush Cuts Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $6.00 - Defense World

May 12, 2025
pulisher
May 10, 2025

Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024) - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Wedbush Adjusts Price Target on WEREWOLF THERAPEUTICS (HOWL) to USD 6.00 | HOWL Stock News - GuruFocus

May 10, 2025
pulisher
May 09, 2025

H.C. Wainwright cuts Werewolf Therapeutics target to $10 By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

H.C. Wainwright cuts Werewolf Therapeutics target to $10 - Investing.com Australia

May 09, 2025
pulisher
May 09, 2025

Wedbush Adjusts Price Target on Werewolf Therapeutics to $6 From $8, Maintains Outperform Rating - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 09, 2025
pulisher
May 09, 2025

Werewolf Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Werewolf Therapeutics (HOWL) Advances Clinical Trials and Expands Educational Initiatives | HOWL Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Werewolf Therapeutics Announces Progress in Clinical Trials and Financial Updates for Q1 2025 - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Renaissance Technologies LLC Decreases Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

May 08, 2025
pulisher
May 06, 2025

JPMorgan Chase & Co. Raises Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

May 06, 2025
pulisher
May 05, 2025

HOWLWerewolf Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

May 05, 2025
pulisher
May 05, 2025

Werewolf Therapeutics (HOWL) Showcases Innovative IBD Treatment Developments | HOWL Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Werewolf Therapeutics reports progress on IBD treatment - Investing.com Australia

May 05, 2025
pulisher
May 05, 2025

Werewolf Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

May 05, 2025

Werewolf Therapeutics Inc Azioni (HOWL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Werewolf Therapeutics Inc Azioni (HOWL) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
RA CAPITAL MANAGEMENT, L.P.
Director
May 14 '25
Buy
0.98
162,539
159,288
6,237,482
RA CAPITAL MANAGEMENT, L.P.
Director
May 13 '25
Buy
0.98
52,974
51,915
6,074,943
MPM BioVentures 2014, L.P.
10% Owner
Mar 27 '25
Sale
1.05
1,963
2,061
3,208,793
EVNIN LUKE
Director
Mar 27 '25
Sale
1.05
2,425
2,546
4,309,860
GADICKE ANSBERT
10% Owner
Mar 27 '25
Sale
1.05
4,386
4,605
6,718,670
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):